Arcutis Biotherapeutics, Inc.

Drug Name	Phase	Indication	Designations	Patent
Roflumilast Cream 0.05%	Phase 3	Atopic Dermatitis	-	-
Roflumilast Foam 0.3%	Phase 3	Scalp Psoriasis	-	-
Topical roflumilast	Phase 3	Chronic Plaque Psoriasis	-	-
ARQ-151 0.3% cream	Phase 3	Chronic Plaque Psoriasis	-	-
Roflumilast Foam	Phase 3	Seborrheic Dermatitis	-	-
Roflumilast Cream	Phase 3	Atopic Dermatitis Eczema	-	-
Vehicle foam	Phase 3	Plaque Psoriasis	-	-
ARQ-151 Active	Phase 3	Atopic Dermatitis Eczema	-	-
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Phase 3	Atopic Dermatitis Eczema	-	-
Roflumilast Cream 0.15%	Phase 3	Atopic Dermatitis Eczema	-	-
Roflumilast 0.3% cream	Phase 3	Chronic Plaque Psoriasis	-	-
ARQ-151 cream 0.3%	Phase 2	Psoriasis	-	-
ARQ-252 cream 0.3%	Phase 2	Chronic Hand Eczema	-	-
ARQ-151 cream 0.5%	Phase 2	Psoriasis	-	-
ARQ-151 cream 0.05%	Phase 2	Atopic Dermatitis (Eczema)	-	-
Roflumilast Cream 0.3%	Phase 2	Plaque Psoriasis	-	-
Roflumilast	Phase 2	Plaque Psoriasis	-	-
ARQ-154	Phase 2	Seborrheic Dermatitis	-	-

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Arcutis Biotherapeutics, Inc.

Market Overview

ARQT News

Catalyst Timeline

ARQ-151 cream 0.05% Phase 2 Est. Readout

FDA PDUFA Date ARQ-154 (standard)

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals